Salta al contenuto principale Salta alla navigazione principale Salta al piè di pagina
Ricerca Pubblicazioni-Brevetti:
9 di 27 brevetti
Abstract: La presente invenzione si colloca nel settore dei dispositivi medici, e più in particolare riguarda un dispositivo impiantabile passivo per la stimolazione elettrica cardiaca, privo di batterie e di elettrocateteri.
Autori: Francesco Alamanni, Matteo Saccocci, Elena Tremoli
2021
Abstract: The present invention relates to new cellular peptides permeable to cell membranes capable of interfering with CAP2/actin association and inhibiting the endocytosis of the ADAM10 enzyme. Also contemplated are pharmaceutical compositions comprising the endocytosis inhibitory peptides of ADAM10 and the related uses in the medical field for the treatment and/or prevention of pathologies in which an increase or accumulation of the beta-amyloid peptide occurs, such for example Alzheimer's Disease, head injury and post-traumatic stress disorder.
2021
Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.
2020
Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.
2020
Abstract: Object of the present invention is the use of inhibitor compounds of the human GTPase Rac1 in the treatment of malaria.
2019
Abstract: The present intervention relates to new peptides that increase the activity of the enzyme ADAM10 by acting at various levels in the cascade of events that leads to the accumulation of the beta-amyloid peptide. Pharmaceutical compositions are also contemplated comprising activator peptides of the enzyme ADAM10 and the related uses in the medical field for the treatment and/or prevention of the pathologies wherein the increase or accumulation of the beta-amyloid peptide occurs, such as Alzheimer's Disease, head injury and post-traumatic stress disorder.
Autori: Monica Maria Grazia Diluca, Elena Marcello, Stefano Musardo, Sebastien Therin, Fabrizio Gardoni
2019
Abstract: The present invention relates to chemical compounds acting through GPR17 receptor for use in the treatment of diseases, in particular for use in chronic and/or acute neurodegenerative diseases, preferably Multiple Sclerosis, inflammatory diseases, pathologies involving the immune system, cardiovascular diseases, renal diseases.
Autori: Maria Pia Abbracchio, Ivano Eberini, Marta Fumagalli, Chiara Parravicini, Cristina Sensi
2019
Abstract: The present invention relates to chemical compounds acting through GPR17 receptor for use in the treatment of diseases, in particular for use in chronic and/or acute neurodegenerative diseases, preferably Multiple Sclerosis, inflammatory diseases, pathologies involving the immune system, cardiovascular diseases, renal diseases.
Autori: Maria Pia Abbracchio, Ivano Eberini, Marta Fumagalli, Chiara Parravicini, Cristina Sensi
2018
Abstract: The present invention relates to chemical compounds acting through GPR17 receptor for use in the treatment of diseases, in particular for use in chronic and/or acute neurodegenerative diseases, preferably Multiple Sclerosis, inflammatory diseases, pathologies involving the immune system, cardiovascular diseases, renal diseases.
Autori: Maria Pia Abbracchio, Ivano Eberini, Marta Fumagalli, Chiara Parravicini, Cristina Sensi
2018